Savan Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 26-06-2024
- Paid Up Capital ₹ 9.14 M
as on 26-06-2024
- Company Age 22 Year, 9 Months
- Last Filing with ROC 31 Mar 2011
- Open Charges ₹ 6.70 Cr
as on 26-06-2024
- Satisfied Charges ₹ 7.62 Cr
as on 26-06-2024
About Savan Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2011. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 9.14 M.
The company currently has active open charges totaling ₹6.70 Cr. The company has closed loans amounting to ₹7.62 Cr, as per Ministry of Corporate Affairs (MCA) records.
Surya Veerapaneni and Anand Veerapaneni serve as directors at the Company.
- CIN/LLPIN
U24239TG2002PTC038625
- Company No.
038625
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Mar 2002
- Date of AGM
30 Sep 2011
- Date of Balance Sheet
31 Mar 2011
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Savan Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Surya Veerapaneni  | Managing Director | 31-Mar-2004 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Anand Veerapaneni | Director | 08-Mar-2002 | Current |
Financial Performance of Savan Pharmaceuticals.
Enhance accessibility to Savan Pharmaceuticals's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Savan Pharmaceuticals?
Unlock access to Savan Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Quali-Care Pharmaceuticals LimitedActive 39 years 1 monthSurya Veerapaneni and Anand Veerapaneni are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 24 Apr 2010 | ₹6.70 Cr | Open |
Centurion Bank Of Punjab Creation Date: 27 Oct 2006 | ₹5.20 Cr | Satisfied |
Bharat Overseas Bank Ltd. Creation Date: 19 Feb 2005 | ₹8.20 M | Satisfied |
How Many Employees Work at Savan Pharmaceuticals?
Unlock and access historical data on people associated with Savan Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Savan Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Savan Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
